Solaraze^®

Partners: Nycomed USA, Inc & Almirall S.A.

A well tolerated treatment offering significant efficacy for actinic keratosis patients

Our proprietary hyaluronic acid gel technology maximises the concentration of the active drug (diclofenac) in the upper layers of the skin. This not only reduces systemic effects, but also greatly improves the efficacy of the drug.

Solaraze® offers an effective and cosmetically acceptable alternative to conventional treatments that are painful or disfiguring. Solaraze® is licensed to Nycomed USA, Inc in the US, Canada & Mexico, and to Almirall S.A. in Europe and Australia. Both partners are actively involved in campaigns to raise awareness of the risks posed by this common condition and the therapeutic options available to physicians.

Solaraze® has been approved and marketed in the US and Europe for several years and recently received registration by the Australian Government (TGA). Since September 2007 it is now commercially available, through a sub-license arrangement with CSL Biotherapies, in Australia, where skin cancer has a particularly high incidence.

For further information on Solaraze®, see the web sites of Nycomed USA and Almirall.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom